Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.

Abstract excerpt

Acquired drug resistance represents a major obstacle to using sunitinib for the treatment of solid tumors. Here, we examined the cellular and molecular alterations in tumors that are associated with acquired brain tumor resistance to sunitinib by using an in vivo model. U87MG tumors obtained from nude mice that received sunitinib (40 mg/kg/day) for 30 days were classified into sunitinib-sensitive and -resistant...

Topics

Join the communities discussing this publication.

• Angiogenesis Inhibitors
• Graft Survival
• Microdialysis
• Neoplasm Transplantation
• Neovascularization, Pathologic